Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

279
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
279
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Association Between Linea Alba Morphology and Abdominal Wall Distensibility During Pneumoperitoneum.

Surgical laparoscopy, endoscopy & percutaneous techniques·2026
Same author

Endogenously generated Dutch-type Aβ non-fibrillar aggregates dysregulate presynaptic neurotransmission in the absence of detectable inflammation.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

5-ALA/SFC Mitigates Tau Toxicity via Lowering Oxidative Stress in a <i>Drosophila</i> Model of Tau Toxicity.

Life (Basel, Switzerland)·2026
Same author

Axonal distribution of mitochondria maintains neuronal autophagy during aging via eIF2β.

eLife·2026
Same author

Rapid liquid-based cytology improves carcinoma cell detection in intraoperative effusion cytology.

Medical molecular morphology·2026
Same author

Peri-renal and renal sinus fat accumulation and diabetic kidney disease in type 2 diabetes: A Japanese cohort study.

Diabetes research and clinical practice·2025
Same journal

Breaking barriers: Enhancing access to dementia clinical trials in the United Kingdom-Insights from the Scientific Advisory Board of the Dame Barbara Windsor Dementia Goals Programme.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

药物开发 药物开发

Toshiharu Suzuki1, Haruka Saito2, Shoichi Kinoshita2

  • 1Tokyo Metropolitan University, Hachioji, Japan.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
概括
此摘要是机器生成的。

来自阿尔卡迪因的p3-Alcß9-19显示在阿尔茨海默氏症中具有潜力.

更多相关视频

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

相关实验视频

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

科学领域:

  • 神经科学和神经退行性疾病
  • 分子生物学和遗传学
  • 药理学和药物发现

背景情况:

  • 阿尔卡迪因 (Clstn3) 是一个突触膜蛋白质,被切割成,包括p3-Alcß37,p3-Alcß40和p3-Alcß9-19.
  • 这些,特别是p3-Alcß9-19,可以恢复神经元模型和阿尔茨海默病 (AD) 鼠标模型中由粉样β oligomers 损害的线粒体功能.
  • 识别p3-Alcß9-19的分子标对于了解其在阿尔茨海默病中的治疗潜力至关重要.

研究的目的:

  • 为了识别和验证质p3-Alcß9-19.9的分子标.
  • 为了分析AD小鼠模型的大脑中的基因表达特征,该小鼠模型接受了p3-Alcß9-19.9的治疗.
  • 在AD相关的基因表达变化的背景下研究p3-Alcß9-19的治疗机制.

主要方法:

  • 将p3-Alcß9-19 (1mg/kg) 给AppNL-F/NLF小鼠 (一种AD模型) 用一个月.
  • 从接受治疗的小鼠和对照小鼠 (接受PBS治疗) 剖析的大脑区域的RNA测序 (RNAseq) 分析.
  • 在小鼠模型和人类AD患者中对基因表达变化的比较分析.

主要成果:

  • p3-Alcß9-19的使用改变了AD小鼠大脑中神经元和非神经元细胞的基因表达.
  • 在人类阿尔茨海默症患者中,许多向下调节的基因在接受p3-Alcß9-19治疗的小鼠中被上调或呈现上调趋势.
  • 相反,在p3-Alcß9-19治疗后的AD小鼠模型中,一些在人类AD患者中升级的基因被正常化.

结论:

  • p3-Alcß9-19通过调节因病原蛋白在大脑中积累而改变的基因表达特征来保护神经元功能.
  • 酸p3-Alcß9-19显示出作为一种治疗剂的潜力,可以保护大脑的平衡,并对抗神经退行.
  • 临床前发现支持对ALC919进行进一步的临床研究,ALC919是p3-Alcß9-19的透皮配方,用于治疗阿尔茨海默病.